This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lim, Y.-P. Articles by Epstein, R. J. Search for Related Content PubMed PubMed Citation Articles by Lim, Y.-P. Articles by Epstein, R. J.

Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers

Implications for Adjuvant Use of Kinase-Inhibitory Drugs

¹ Division of Medical Sciences and ³ Department of Surgical Oncology, National Cancer Centre, Singapore; ² Department of General Surgery, Singapore General Hospital, Singapore; ⁴ Oregon Cancer Institute, University of Oregon, Portland, Oregon; and ⁵ Department of Medicine, University of Hong Kong, Hong Kong

ABSTRACT

Purpose: Small-molecule growth factor receptor inhibitors block cell growth in vitro and downstream signaling in vivo, but controlled trials in patients with advanced solid tumors have yielded disappointing response rates. To clarify this discrepancy, we compared the patterns of tyrosine phosphoprotein expression in human cancer cells and primary tumors.

Experimental Design: Immunoaffinity chromatography, two-dimensional electrophoresis, and antiphosphotyrosine immunoblotting were combined with mass spectrometry to determine the phosphoproteomic signatures of 40 matched normal and malignant tissues from patients with breast or liver cancer. The identities and abundance of the detected tyrosine phosphoproteins were compared with those of ligand-responsive A431 cells.

Results: Patterns of tyrosine-phosphorylated proteins are similar among normal tissues of the same origin but vary markedly between different tissues. Primary breast tumors exhibit a strikingly homogeneous tyrosine phosphorylation profile, whereas liver cancers display greater phosphoproteomic diversity. The main breast-tumor-specific tyrosine phosphoproteins are cytoskeletal molecules (actin, tubulin, and vimentin) and molecular chaperones (Hsp70, Hsc71, and Grp75). In contrast, control studies in ligand-stimulated A431 human cancer cells revealed an additional phosphorylated subset of promitogenic phosphoproteins (Grb2, Shc, Jnk2, phospholipase C-, and phosphatidylinositol 3'-kinase).

Conclusions: Identification of cytoskeletal and stress proteins as the most abundant tyrosine phosphoproteins in breast tumors implicates these molecules, rather than promitogenic effectors, as the prime stoichiometric substrates for kinase-inhibitory anticancer drugs in vivo. Because phosphorylated cytoskeletal proteins and chaperones mediate cell motility and apoptotic resistance, respectively, these data raise the intriguing possibility that small-molecule tyrosine kinase inhibitors may be of greatest value either as adjuvant antimetastatic/-invasive drugs or as chemo-/radiosensitizers.

This article has been cited by other articles:

				Y. Chen, L.-Y. Choong, Q. Lin, R. Philp, C.-H. Wong, B.-K. Ang, Y.-L. Tan, M.-C.-S. Loh, C.-L. Hew, N. Shah, et al. Differential Expression of Novel Tyrosine Kinase Substrates during Breast Cancer Development Mol. Cell. Proteomics, December 1, 2007; 6(12): 2072 - 2087. [Abstract] [Full Text] [PDF]

				L.-Y. Choong, S. Lim, M. C.-S. Loh, X. Man, Y. Chen, W. Toy, M. Pan, C.-S. Chen, A. Poonepalli, M. P. Hande, et al. Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics Mol. Cancer Ther., November 1, 2007; 6(11): 2828 - 2842. [Abstract] [Full Text] [PDF]

				S. M. Rodriguez-Pinilla, D. Sarrio, E. Honrado, G. Moreno-Bueno, D. Hardisson, F. Calero, J. Benitez, and J. Palacios Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas J. Clin. Pathol., September 1, 2007; 60(9): 1006 - 1012. [Abstract] [Full Text] [PDF]

				F. Di Modugno, L. DeMonte, M. Balsamo, G. Bronzi, M. R. Nicotra, M. Alessio, E. Jager, J. S. Condeelis, A. Santoni, P. G. Natali, et al. Molecular Cloning of hMena (ENAH) and Its Splice Variant hMena+11a: Epidermal Growth Factor Increases Their Expression and Stimulates hMena+11a Phosphorylation in Breast Cancer Cell Lines Cancer Res., March 15, 2007; 67(6): 2657 - 2665. [Abstract] [Full Text] [PDF]

				S. S. Mambula and S. K. Calderwood Heat Shock Protein 70 Is Secreted from Tumor Cells by a Nonclassical Pathway Involving Lysosomal Endosomes J. Immunol., December 1, 2006; 177(11): 7849 - 7857. [Abstract] [Full Text] [PDF]

				R. J. Epstein Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment Clin. Cancer Res., August 1, 2005; 11(15): 5337 - 5341. [Abstract] [Full Text] [PDF]

				Y. P. Lim Mining the Tumor Phosphoproteome for Cancer Markers Clin. Cancer Res., May 1, 2005; 11(9): 3163 - 3169. [Abstract] [Full Text] [PDF]